The success that Gene One has had in eight short years has presented a quandary concerning the strategic path Gene One's future. Should Gene One execute of strategy of constancy and continuity Will this type of strategy keep Gene One's competitors from gaining ground on Gene One's share of the market place over the next several years After careful consideration of these perplexing questions, the leadership of Gene One has decided an alternate strategy, as Gene One has not achieved all that they have by continuity alone. Gene One has taken risks that were founded on sound strategy and faith that intelligent men and women with innovative ideas and unsurpassed drive and passion cannot be stopped. These type of people are winners and they accomplish their goals. These factors set the stage for constantly evolving ideas that provided multiple benefits that were accomplished in record time. Seldom has this type of success been achieved in the biotech industry which is considered a risky business in some cases. That said, the Gene One leadership has decided that Gene One must be given an opportunity to experience its maximum growth potential before some piggy back organization with lucrative investors siphon off strategic market areas previously held by Gene One.
As with any strategy, there are risks involved. ...
As with any strategy, there are risks involved. However, due to Gene One's financial stability, strong leadership and growth potential, these risks are just obstacle that can be turned into positive opportunities. Please note the following:
Economic Packages (founders of Gene One, board members and essential personnel)
While IPO capital is of extreme importance concerning Gene One's preparations to go public, this topic can not be considered if it does not include job security and economic packages that reward the founders, board members and essential personnel at Gene One for their contributions that have led to the meteoric rise of Gene One over an eight-year timeframe. This is not a difficult problem to solve due to the strategy that will restructure and diversify Gene One while maintaining its technological and competitive edge over the competition.
The following is a brief bio of Charles Jones, Gene One's marketing officer:
"Two years after Gene Ones's start-up, Don Ruiz, Chief Executive Officer for Gene One, recruited 35-year-old Charles because of his reputation for "smart" risk taking and his biotechnology connections. Don saw him as the perfect person to develop and implement Gene One marketing strategy. Self-confident and moral, Charles easily garners trust for himself and the company."
Ruiz, Gene One Company Overview Report
Gene One 4
The Gene One leadership feels that while Charles is limited in his abilities to personally design and implement a marketing infrastructure, his overall talents and track record suggests that